IB’s “Approaches To Learning” (ATL’s) Essential For AI Era
At the heart of the IB’s success are its Approaches to Learning (ATLs), which foster a problem-solving mindset and produce ...
Blueprint Medicines projects $680M-$710M AYVAKIT revenue in 2025 with 45% growth
Q4 2024 Management View CEO Kate Haviland highlighted that Blueprint Medicines achieved $479 million in product revenue for 2024, driven by AYVAKIT’s 135% annual growth. The company expects AYVAKIT to ...